Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to Outperform at Leerink Partners

Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a market perform rating to an outperform rating in a research note released on Wednesday, Marketbeat reports. The firm currently has $834.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $762.00.

REGN has been the subject of a number of other reports. Bank of America reissued an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Truist Financial decreased their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Oppenheimer decreased their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Finally, Piper Sandler lowered their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Up 2.8 %

NASDAQ REGN opened at $716.72 on Wednesday. Regeneron Pharmaceuticals has a 52 week low of $642.00 and a 52 week high of $1,211.20. The firm has a market capitalization of $78.76 billion, a price-to-earnings ratio of 17.74, a PEG ratio of 1.60 and a beta of 0.08. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a fifty day moving average of $718.04 and a two-hundred day moving average of $916.32.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The firm had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the previous year, the company earned $11.86 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals will post 37.75 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.49%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. International Assets Investment Management LLC raised its stake in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after buying an additional 879,916 shares during the last quarter. Proficio Capital Partners LLC raised its stake in Regeneron Pharmaceuticals by 92,865.3% in the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock worth $156,284,000 after acquiring an additional 219,162 shares during the last quarter. Worldquant Millennium Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth about $127,489,000. KBC Group NV grew its stake in Regeneron Pharmaceuticals by 296.7% during the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock valued at $97,338,000 after purchasing an additional 102,198 shares during the last quarter. Finally, Icon Wealth Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after purchasing an additional 75,569 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.